SCHEMBL1720922

SCHEMBL1720922

O=c1[nH]c2snc(CN3CCCC3)c2c2ccc(F)cc12

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 7/20 0.40
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
TNKS O95271 2/20 0.37
PARP2 Q9UGN5 1/20 0.37
MPO P05164 2/20 0.37
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PLK1 P53350 1/20 0.35
KDM5B Q9UGL1 1/20 0.35
PIM1 P11309 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
PARP3 Q9Y6F1 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CDC7 O00311 1/20 0.34
ROCK1 Q13464 1/20 0.34
DBF4 Q9UBU7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720184 0.86 PIM1 (0.47) PARP1CDK4CCND1SMN1; SMN2PIM1
SCHEMBL1719983 0.84 PARP1 (0.39) PARP1CDK4CCND1TNKSMPO
SCHEMBL1719946 0.78 PARP1 (0.41) PARP1TNKSMPOPIM1PIM2
SCHEMBL1720724 0.77 PARP1 (0.40) PARP1CDK4CCND1TNKSPARP2
SCHEMBL1719923 0.76 PARP1 (0.42) PARP1CDK4CCND1TNKSPARP2
Hydrochloric Acid SCHEMBL4069890 0.76 PARP1 (0.41) PARP1CDK4CCND1TNKSPARP2
SCHEMBL1719830 0.74 PARP1 (0.42) PARP1TNKSALDH1A1
SCHEMBL1721010 0.71 KMT2A (0.48) PARP1TNKSPARP2MPOKDM4E
SCHEMBL1721096 0.69 PARP1 (0.43) PARP1CDK4CCND1TNKSPARP2
SCHEMBL1721121 0.64 KMT2A (0.43) PARP1CDK4CCND1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 PARP1 1/4885CDK4 2571/4885CCND1 3065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.